Share on LinkedInShare on LinkedIn

ARTICLE · 18 JUNE 2020

COVID-19 Licensing Challenges

The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking flexible approaches to regulation during the COVID-19 outbreak. [1]

United KingdomCoronavirus (COVID-19)

The taking of new therapies and technologies forward to meet the challenges of COVID-19 is happening at previously unprecedented rates. MHRA is taking flexible approaches to regulation during the COVID-19 outbreak.1 This includes providing expedited scientific advice, and rapid reviews of clinical trials applications.

The speed of progress means that it is challenging for you to know:

  • that you have freedom to operate (FTO) i.e. you will not infringe anyone else's therapy or technology, and do not need a licence; and
  • on what terms to license in necessary technologies and license out your own technology, when the focus is on just getting help to patients now.

Whilst you should still look at your FTO position, there are some exemptions and non-assert/licensing arrangements that might help you out in the short-term.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from